TY - JOUR
T1 - Comparison of Active Surveillance to Stereotactic Radiosurgery for the Management of Patients with an Incidental Frontobasal Meningioma—A Sub-Analysis of the IMPASSE Study
AU - Islim, Abdurrahman I.
AU - Mantziaris, Georgios
AU - Pikis, Stylianos
AU - Chen, Ching Jen
AU - Bunevicius, Adomas
AU - Peker, Selçuk
AU - Samanci, Yavuz
AU - Nabeel, Ahmed M.
AU - Reda, Wael A.
AU - Tawadros, Sameh R.
AU - El-Shehaby, Amr M.N.
AU - Abdelkarim, Khaled
AU - Emad, Reem M.
AU - Delabar, Violaine
AU - Mathieu, David
AU - Lee, Cheng Chia
AU - Yang, Huai Che
AU - Liscak, Roman
AU - May, Jaromir
AU - Alvarez, Roberto Martinez
AU - Moreno, Nuria Martinez
AU - Tripathi, Manjul
AU - Kondziolka, Douglas
AU - Speckter, Herwin
AU - Albert, Camilo
AU - Bowden, Greg N.
AU - Benveniste, Ronald J.
AU - Lunsford, Lawrence Dade
AU - Sheehan, Jason P.
AU - Jenkinson, Michael D.
N1 - Publisher Copyright:
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Meningioma is a common incidental finding, and clinical course varies based on anatomical location. The aim of this sub-analysis of the IMPASSE study was to compare the outcomes of patients with an incidental frontobasal meningioma who underwent active surveillance to those who underwent upfront stereotactic radiosurgery (SRS). Data were retrospectively collected from 14 centres. The active surveillance (n = 28) and SRS (n = 84) cohorts were compared unmatched and matched for age, sex, and duration of follow-up (n = 25 each). The study endpoints included tumor progression, new symptom development, and need for further intervention. Tumor progression occurred in 52.0% and 0% of the matched active surveillance and SRS cohorts, respectively (p < 0.001). Five patients (6.0%) treated with SRS developed treatment related symptoms compared to none in the active monitoring cohort (p = 0.329). No patients in the matched cohorts developed symptoms attributable to treatment. Three patients managed with active surveillance (10.7%, unmatched; 12.0%, matched) underwent an intervention for tumor growth with no persistent side effects after treatment. No patients subject to SRS underwent further treatment. Active monitoring and SRS confer a similarly low risk of symptom development. Upfront treatment with SRS improves imaging-defined tumor control. Active surveillance and SRS are acceptable treatment options for incidental frontobasal meningioma.
AB - Meningioma is a common incidental finding, and clinical course varies based on anatomical location. The aim of this sub-analysis of the IMPASSE study was to compare the outcomes of patients with an incidental frontobasal meningioma who underwent active surveillance to those who underwent upfront stereotactic radiosurgery (SRS). Data were retrospectively collected from 14 centres. The active surveillance (n = 28) and SRS (n = 84) cohorts were compared unmatched and matched for age, sex, and duration of follow-up (n = 25 each). The study endpoints included tumor progression, new symptom development, and need for further intervention. Tumor progression occurred in 52.0% and 0% of the matched active surveillance and SRS cohorts, respectively (p < 0.001). Five patients (6.0%) treated with SRS developed treatment related symptoms compared to none in the active monitoring cohort (p = 0.329). No patients in the matched cohorts developed symptoms attributable to treatment. Three patients managed with active surveillance (10.7%, unmatched; 12.0%, matched) underwent an intervention for tumor growth with no persistent side effects after treatment. No patients subject to SRS underwent further treatment. Active monitoring and SRS confer a similarly low risk of symptom development. Upfront treatment with SRS improves imaging-defined tumor control. Active surveillance and SRS are acceptable treatment options for incidental frontobasal meningioma.
KW - Asymptomatic
KW - Incidental
KW - Meningioma
KW - Radiosurgery
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=85125935758&partnerID=8YFLogxK
U2 - 10.3390/cancers14051300
DO - 10.3390/cancers14051300
M3 - Article
AN - SCOPUS:85125935758
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 5
M1 - 1300
ER -
